Last reviewed · How we verify
NCT05137431
High-flow Nasal Oxygenation and Non-invasive Ventilation Strategies for the Treatment of Covid-19 Pneumonia
trial testing HFNO and NIV in COVID-19 Pneumonia in 30 participants. Completed in 30 April 2022.
30 April 2022
Quick facts
| Lead sponsor | Medipol University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 8 December 2021 |
| Primary completion | 30 April 2022 |
| Estimated completion | 30 April 2022 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- HFNO and NIV
Conditions studied
- COVID-19 Pneumonia — all drugs for COVID-19 Pneumonia →
- COVID-19 Acute Respiratory Distress Syndrome — all drugs for COVID-19 Acute Respiratory Distress Syndrome →
Sponsor
Medipol University
Who can join
18 and older, any sex, with COVID-19 Pneumonia or COVID-19 Acute Respiratory Distress Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
HFNO and NIV strategies are the most commonly used strategies for the treatment of hypoxia in patients with a diagnosis of COVID-19 who are still followed in the intensive care unit, but there is no study comparing the two yet. In our prospective study, we aimed to compare these two treatment modalities. The primary goal is that the treatment is successful (weaned off HFNO/weaned off NIV: No need for HFNO or NIV and the patient recovers without the need for intubation). Failure will be evaluated as the need for intubation during treatment or the patient's death. Secondary aim is failure of treatment and discharge of patients from intensive care to service or home.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05137431
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19 Pneumonia
Currently open trials in the same condition.
- NCT06601998 — Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19. · recruiting
- NCT06501599 — AI-based System for Assessing Suspected Viral Pneumonia Related Lung Changes · recruiting
- NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
- NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
- NCT06927622 — Corona Virus Disease 2019 Cohort Study · recruiting
Other Medipol University trials
Trials by the same sponsor.
- NCT07277803 — Device-Based vs Manual Sensory Training in Low Back Pain · NA · not yet recruiting
- NCT07214636 — Development and Investigation of the ApneaTheraPlay · NA · not yet recruiting
- NCT07534475 — Venous Tourniquet vs. Arterial Tourniquet for Seizure Monitoring in ECT · NA · not yet recruiting
- NCT07534488 — Sacral Erector Spinae Plane Block in Pilonidal Sinus Surgery · NA · not yet recruiting
- NCT07525648 — Comparison of the Effects of Sevoflurane and Desflurane on Optic Nerve Sheath Diameter During Laparoscopic Surgery · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05137431 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medipol University
- Last refreshed: 11 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05137431.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing